Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen resubmits denosumab

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amgen's Prolia (denosumab) is back under review at FDA for treatment of postmenopausal osteoporosis with a July 25 user fee date, the company announced Feb. 19. The firm's response to the October 2009 "complete response" letter was designated a Class II resubmission. Analysts had hoped for a Class I designation, which would have meant a two-month review (1Pharmaceutical Approvals Monthly, January 2010). The action letter, which addressed treatment and prevention of PMO, requested additional information on the design of Amgen's proposed post-marketing surveillance program and updated safety data. FDA also issued a "complete response" on the indications for prevention of bone loss due to hormone ablation therapy in breast and prostate cancer (2"The Pink Sheet" DAILY, Oct. 21, 2009). Amgen said that it continues to work with FDA "to determine appropriate next steps" for the other Prolia indications
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS004353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel